UNSPSC 51182708: Metformin/saxagliptin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182708 Metformin/saxagliptin is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and medical supplies procured by public health agencies. However, the single recent opportunity in the source is a mismatch: Seminole County, Florida's IFB60459723LAS solicitation (posted June 30, 2026, due July 26, 2023) sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for community health initiatives—neither of which are metformin or saxagliptin products. The county procurement does not reflect the code's nominal scope and appears to be a tagging error in the underlying source data.

The source provides no additional recent opportunities under this code that align with its actual pharmaceutical scope, making it impossible to characterize the issuing-body mix, geographic spread, or representative solicitations for metformin/saxagliptin procurement at the state and local level based on this record alone. Until opportunities properly tagged under this code surface, vendors should verify whether state and local demand for these specific diabetes therapeutics is being captured under this UNSPSC designation or consolidated under broader pharmaceutical or pharmacy benefit codes.